We therefore conducted a proteomic analyses of ARMS to characterize the protein profile associated with PAX3-FOXO1 fusion with cross-reference to the gene expression data, with the aim of identifying efficient therapeutic targets in this tumor that could be treated using easy methods of administration (i.e., oral administration). This evidence concerns the gene FOXO1 and neoplasm.